# Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients

> **NCT02042690** · PHASE3 · COMPLETED · sponsor: **Peking University** · enrollment: 131 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **PROCEDURE:** Haplo-identical HSCT
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02042690
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2018-02
- **Final completion:** 2019-04
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2019-05-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042690, "Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02042690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*